Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Department of Cardiology, Golden Jubilee National Hospital, Glasgow, United Kingdom.
JACC Cardiovasc Interv. 2021 Sep 27;14(18):2047-2055. doi: 10.1016/j.jcin.2021.06.009. Epub 2021 Aug 25.
The aim of this study was to determine the safety of selective intracoronary hypothermia during primary percutaneous coronary intervention (PPCI) in patients with anterior ST-segment elevation myocardial infarction (STEMI).
Selective intracoronary hypothermia is a novel treatment designed to reduce myocardial reperfusion injury and is currently being investigated in the ongoing randomized controlled EURO-ICE (European Intracoronary Cooling Evaluation in Patients With ST-Elevation Myocardial Infarction) trial (NCT03447834). Data on the safety of such a procedure during PPCI are still limited.
The first 50 patients with anterior STEMI treated with selective intracoronary hypothermia during PPCI were included in this analysis and compared for safety with the first 50 patients randomized to the control group undergoing standard PPCI. In-hospital mortality, occurrence of rhythm or conduction disturbances, stent thrombosis, onset of heart failure during the procedure, and subsequent hospital admission were assessed.
In-hospital mortality was 0%. One patient in both groups developed cardiogenic shock. Atrial fibrillation occurred in 0 and 3 patients (P = 0.24), and ventricular fibrillation occurred in 5 and 3 patients (P = 0.72) in the intracoronary hypothermia group and control group, respectively. Stent thrombosis occurred in 2 patients in the intracoronary hypothermia group; 1 instance was intraprocedural, and the other occurred following interruption of dual-antiplatelet therapy consequent to an intracranial hemorrhage 6 days after enrollment. No stent thrombosis was observed in the control group (P = 0.50).
Selective intracoronary hypothermia during PPCI in patients with anterior STEMI can be implemented within the routine of PPCI and seems to be safe. The final safety results will be reported at the end of the trial.
本研究旨在确定在前壁 ST 段抬高型心肌梗死(STEMI)患者中进行经皮冠状动脉介入治疗(PPCI)时选择性冠状动脉内低温的安全性。
选择性冠状动脉内低温是一种新型治疗方法,旨在减少心肌再灌注损伤,目前正在进行的随机对照 EURO-ICE(欧洲 ST 段抬高型心肌梗死患者冠状动脉内冷却评估)试验(NCT03447834)中进行研究。关于这种方法在 PPCI 期间的安全性的数据仍然有限。
该分析纳入了前壁 STEMI 患者中接受选择性冠状动脉内低温治疗的前 50 例患者,并与接受标准 PPCI 的随机分组的前 50 例患者进行安全性比较。评估院内死亡率、心律失常或传导障碍的发生、支架血栓形成、术中心力衰竭的发生以及随后的住院治疗。
院内死亡率为 0%。两组各有 1 例患者发生心源性休克。心房颤动分别在 0 例和 3 例患者中发生(P=0.24),心室颤动分别在 5 例和 3 例患者中发生(P=0.72),低温组和对照组。低温组中有 2 例患者发生支架血栓形成,1 例为术中发生,另 1 例发生在入组后 6 天因颅内出血而中断双联抗血小板治疗后。对照组未观察到支架血栓形成(P=0.50)。
在前壁 STEMI 患者中进行 PPCI 时,可以在 PPCI 的常规操作中实施选择性冠状动脉内低温,并且似乎是安全的。最终安全性结果将在试验结束时报告。